Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Completed2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03914300Phase 2Active Not Recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

NCT02973997Phase 2Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT01811212Phase 2Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Showing all 3 trials

Research Network

Activity Timeline